All filters
Slidesets
Elvitegravir pharmacokinetics during Pregnancy and Postpartum- Angela Colbers
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2018
Slidesets
Clinical Pharmacology of Integrase Inhibitors - Giovanni Di Perri, MD, PhD
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2018
Slidesets
Clinical case presentation - Marta Boffito, MD, PhD, FRCP
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2018
Slidesets
Pharmacokinetic and virological efficacy of dolutegravir (50 mg BID) containing regimen in association with rifampin in HIV-infected patients using Dried Blood Spot: ANRS-12313 NAMSAL sub-study in Cameroon- Le
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2018
Slidesets
First report of dolutegravir unbound plasma concentrations during pregnancy in HIV-positive women- Pauline Bollen
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2018
Slidesets
Update on DDI guidelines of the FDA - in vitro- Xinning Yang, PhD
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2018
Slidesets
Update on DDI guidelines of the FDA - in vivo- Kellie Reynolds, PharmD
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2018
Slidesets
How to End the Global HCV Epidemic - the role of injectables- David Thomas, MD, PhD
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2018
Slidesets
Medication safety issues associated with currently used first-line antiretroviral regimens in Uganda- Kay Seden
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2018
Slidesets
Intraindividual comparison of efavirenz, atazanavir, or ritonavir plasma pharmacokinetics before and during 21-days of vaginally administered hormone contraception- Kimberly Scarsi, PharmD, MS, FCCP
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2018
Slidesets
Rifabutin (RBT) Decreases Cabotegravir (CAB) Exposure following Oral Co-administration- Patel
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2018
Slidesets
Rifabutin PK and Safety among HIV/TB Coinfected Children Receiving Lopinavir- Holly Rawizza
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2018
Slidesets
Clinical Pharmacology of HIV Pre-Exposure Prophylaxis (PrEP) – Where are we now?- Craig Hendrix
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2018
Slidesets
Population Pharmacokinetics and Pharmacokinetics/Pharmacodynamics of Etravirine in HIV-positive Children Ages 1-<6 Years- Mustafa IBrahim
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2018
Slidesets
Differential brain tissue penetration of antiretrovirals and fluconazole- Katelyn Pastick
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2018
Meeting
European HIV Clinical Forum 2017
Slidesets
State of the ART: Integrase Inhibitors Resistance- Charles Boucher, MD, PhD
Presented at:
European HIV Clinical Forum 2017
Slidesets
What is the virological support for reduced drug regimens?- Anne-Geneviève Marcelin, MD
Presented at:
European HIV Clinical Forum 2017
Slidesets
What is the clinical support for reduced drug regimens?- David Cooper, MD, DSc
Presented at:
European HIV Clinical Forum 2017
Slidesets
Real Life Experience of Dolutegravir and Lamivudine Dual Therapy as a Switching Regimen in HIV-TR Cohort.- D. Yağcı-Çağlayık
Presented at:
European HIV Clinical Forum 2017
Slidesets
Dolutegravir used in real-life provides high rates of virological response in conjunction with a rare emergence of integrase resistance.- D. Armenia
Presented at:
European HIV Clinical Forum 2017
Slidesets
French national survey of resistance to integrase inhibitors in a context of routine hospital care (ANRS AC11 Virology Network).- A.G. Marcelin
Presented at:
European HIV Clinical Forum 2017
Slidesets
Clinical case presentation- Christina Mussini, MD
Presented at:
European HIV Clinical Forum 2017
Slidesets
In-vitro selection of resistance mutations to dolutegravir outside HIV-1 integrase.- Dr. Olivier Delelis
Presented at:
European HIV Clinical Forum 2017